Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 08, 2024

SELL
$1.65 - $3.94 $115,244 - $275,189
-69,845 Reduced 16.37%
356,740 $1.33 Million
Q3 2023

Oct 31, 2023

BUY
$2.02 - $5.04 $216,337 - $539,773
107,098 Added 33.52%
426,585 $904,000
Q2 2023

Aug 11, 2023

SELL
$4.76 - $6.59 $27,960 - $38,709
-5,874 Reduced 1.81%
319,487 $1.52 Million
Q1 2023

May 11, 2023

BUY
$4.24 - $11.12 $21,373 - $56,055
5,041 Added 1.57%
325,361 $1.85 Million
Q4 2022

Feb 13, 2023

BUY
$9.86 - $23.83 $217,334 - $525,260
22,042 Added 7.39%
320,320 $3.23 Million
Q3 2022

Nov 14, 2022

SELL
$21.04 - $36.06 $49,948 - $85,606
-2,374 Reduced 0.79%
298,278 $6.68 Million
Q2 2022

Aug 15, 2022

BUY
$17.78 - $42.39 $448,180 - $1.07 Million
25,207 Added 9.15%
300,652 $7.45 Million
Q1 2022

May 12, 2022

BUY
$29.67 - $60.28 $18,276 - $37,132
616 Added 0.22%
275,445 $10.7 Million
Q4 2021

Feb 10, 2022

BUY
$47.84 - $64.34 $452,375 - $608,399
9,456 Added 3.56%
274,829 $16.1 Million
Q3 2021

Nov 10, 2021

BUY
$59.27 - $95.73 $1.98 Million - $3.2 Million
33,473 Added 14.43%
265,373 $15.7 Million
Q2 2021

Aug 11, 2021

BUY
$67.25 - $92.52 $4.66 Million - $6.41 Million
69,304 Added 42.62%
231,900 $20.1 Million
Q1 2021

May 12, 2021

BUY
$72.16 - $117.4 $11.7 Million - $19.1 Million
162,596 New
162,596 $13.4 Million
Q3 2018

Nov 13, 2018

SELL
$8.75 - $16.29 $54,906 - $102,219
-6,275 Closed
0 $0
Q2 2018

Aug 14, 2018

SELL
$9.16 - $13.48 $45,470 - $66,914
-4,964 Reduced 44.17%
6,275 $71,000
Q1 2018

May 15, 2018

SELL
$6.3 - $13.77 $77,011 - $168,324
-12,224 Reduced 52.1%
11,239 $110,000
Q4 2017

Feb 14, 2018

SELL
$3.94 - $6.64 $126 - $212
-32 Reduced 0.14%
23,463 $143,000
Q3 2017

Nov 14, 2017

BUY
$2.6 - $4.31 $61,087 - $101,263
23,495
23,495 $93,000

Others Institutions Holding FATE

About FATE THERAPEUTICS INC


  • Ticker FATE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,000,304
  • Market Cap $99.9M
  • Description
  • Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...
More about FATE
Track This Portfolio

Track Panagora Asset Management Inc Portfolio

Follow Panagora Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Panagora Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Panagora Asset Management Inc with notifications on news.